Hiệu quả điều trị của hóa trị liệu có chứa ramucirumab ở bệnh nhân ung thư dạ dày sản xuất alpha-fetoprotein

Bergstrand CG, Czar B (1956) Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 8:174–179 Smith CJ, Ajdukiewicz A, Kelleher PC (1983) Concanavalin-a-affinity molecular heterogeneity of human hepatoma AFP and cord-serum AFP. Ann N Y Acad Sci 417:69–74 Norgaard-Pedersen B, Albrechtsen R, Teilum G (1975) Serum alphafoetoprotein as a marker for endodermal sinus tumour (yolk sac tumour) or a vitelline component of “teratocarcinoma.” Acta Pathologica et Microbiologica Scand Sec A Pathol 83(6):573–589 European Association for the Study of the Liver (2019) EASL clinical practice guidelines management of hepatocellular carcinoma. J Hepatol 69(1):182–236 Metzgeroth G, Strobel P, Baumbusch T et al (2010) Hepatoid adenocarcinoma review of the literature illustrated by a rare case originating in the peritoneal cavity. Onkologie 33:263–269 Kinjo T, Taniguchi H, Kushima R et al (2012) Histologic and immunohistochemical analyses of α-fetoprotein-producing cancer of the stomach. Am J Surg Pathol 36:56–65 Yamagata T, Yamagata Y, Nakanishi M et al (2004) A case of primary lung cancer producing alpha-fetoprotein. Can Respir J 11:504–506 Matsueda K, Yamamoto H, Yoshida Y et al (2006) Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP). J Gastroenterol 41:1011–1019 Devi NR, Sathyalakshmi R, Devi J et al (2015) Hepatoid adenocarcinoma of the gall bladder-a rare variant. J Clin Diagn Res JCDR. https://doi.org/10.7860/JCDR/2015/10799.6324 Cappetta A, Bergamo F, Mescoli C et al (2012) Hepatoid adenocarcinoma of the colon: what should we target? Pathol Oncol Res 18:93–96 Bourreille J, Metayer P, Sauger F et al (1970) Existence of alpha feto protein during gastric-origin secondary cancer of the liver. Presse Med 78:1277–1278 McIntire KR, Waldmann TA, Moertel CG et al (1975) Serum alphafetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res 35(4):991–996 Chang YC, Nagasue N, Kohno H et al (1990) Clinicopathologic features and long-term results of alphafetoprotein-producing gastric cancer. Am J Gastroenterol 85(11):1480–1485 Adachi Y, Tsuchihashi J, Shiraishi N et al (2003) AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 65(2):95–101 Bozkaya Y, Demirci NS, Kurtipek A et al (2017) Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Mol Clin Oncol 7(2):267–274 Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39 Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235 Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16(7):859–870 Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296 Inagawa S, Shimazaki J, Hori M et al (2001) Hepatoid adenocarcinoma of the stomach. Gastric Cancer 4(1):43–52 Inoue M, Sano T, Kuchiba A et al (2010) Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer. Br J Surg 97(7):1056–1061 Yoshizawa J, Ishizone S, Ikeyama M et al (2017) Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature. BMC Cancer 17(1):368 He R, Yang Q, Dong X et al (2017) Clinicopathologic and prognostic characteristics of alpha-fetoprotein-producing gastric cancer. Oncotarget 8(14):23817–23830 Wang Y-K, Shen L, Jiao Xi et al (2018) Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. World J Gastroenterol 24(2):266–273 Li N, Bai C, Zhang R et al (2021) Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. Translat Oncolo 14(2):101004 Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458 Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697 Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471 Yoshioka M, Inoue N, Someda H et al (2011) A case of AFP-producing gastric cancer resected after efficient S-1/CDDP combination chemotherapy. Gan To Kagaku Ryoho 38(1):105 Fukuda K, Ito S, Shimizu K et al (2013) Retrospective analysis concerning AFP-producing gastric cancer. Gan Kagaku Ryoho 40(2):191 Kunoki N, Nishiyama R, Ryuzaki H et al (2008) A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy. Nihon Shokakibyo Gakkai Zasshi 105(10):1489 Arakawa Y, Tamura M, Aiba K et al (2017) Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report. Oncol Lett 14(3):3039–3042 Takada J, Araki H, Ozawa N et al (2019) Effective treatment of cytotoxic agent refractory alpha-fetoprotein-producing gastric cancer with ramucirumab: a case report and review of the literature. J Gastrointest Canc 50:556–559 Iida A, Katayama K, Yamaguchi A (2013) Five-year survival of alpha-fetoprotein-producing gastric cancer with synchronous liver metastasis: a case report. J Gastric Cancer 13:58–64 Fang YU, Wang L, Yang N et al (2015) Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases. Oncol Lett 10:3021–3025 Di Bartolomeo M, Niger M, Tirino G et al (2018) Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the ramoss study. Target Oncol 13(2):227–234 Lu J, Ding Y, Chen Y et al (2021) Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. Nat Commun 12(1):3946 Liu D, Li B, Yan B et al (2020) The clinicopathological features and prognosis of serum AFP positive gastric cancer: a report of 16 cases. Int J Clin Exp Pathol 13(9):2439–2446 Yamashita T, Forgues M, Wang W et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461 Shan YF, Huang YL, Xie YK et al (2011) Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol 28:1012–1016 Zucman-Rossi J, Villanueva A, Nault JC et al (2015) Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149:1226–1239 Koide N, Nishio A, Igarashi J et al (1999) Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis, and angiogenesis. Am J Gastroenterol 94:1658–1663 Kamei S, Kono K, Amemiya H et al (2003) Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J Gastroenterol 38:540–547 Wang Y, Sun L, Li Z et al (2019) Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer 22:1183–1192